Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451991 | 0.89 | NOTUM (0.38) | HTR3ASIRT2 | |
| SCHEMBL24252953 | 0.89 | NOTUM (0.38) | HTR3ASIRT2 | |
| SCHEMBL30768292 | 0.80 | AKT1 (0.40) | PARP1 | |
| SCHEMBL24750128 | 0.80 | AKT1 (0.40) | PARP1 | |
| SCHEMBL153211 | 0.79 | AHR (0.45) | PARP1 | |
| SCHEMBL29797722 | 0.79 | HTR3A (0.39) | HTR3APARP1 | |
| SCHEMBL4107808 | 0.76 | PARP1 (0.39) | HTR3APARP1 | |
| SCHEMBL24200079 | 0.76 | PARP1 (0.35) | PARP1 | |
| SCHEMBL16004982 | 0.76 | PARP1 (0.54) | PARP1 | |
| SCHEMBL8118010 | 0.76 | GAA (0.39) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2448941-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| EP-0482108-B1 | SUBSTITUTED 2-IMIDAZOLINES AND PREPARATION AND USE THEREOF | NOVO NORDISK AS (DK) | 1996-03-20 | — | — | EP | disclosed |
| US-5262430-A | Antidiabetic agent lowers blood glucose in mammals in type 2 non insulin dependent diabetes | NOVO NORDISK A/S (DK) | 1993-11-16 | — | — | US | disclosed |
| EP-0482108-A1 | SUBSTITUTED 2-IMIDAZOLINES AND PREPARATION AND USE THEREOF. | NOVO NORDISK AS (DK) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991000862-A1 | SUBSTITUTED 2-IMIDAZOLINES AND PREPARATION AND USE THEREOF | NOVO NORDISK A/S (DK) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | HTR3A 3016/4885PARP1 1703/4885SIRT2 2428/4885 |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | HTR3A 3135/4885PARP1 2803/4885SIRT2 3458/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | HTR3A 3016/4885PARP1 1703/4885SIRT2 2428/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | HTR3A 3319/4885PARP1 1776/4885SIRT2 3762/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | HTR3A 1069/4885PARP1 3072/4885SIRT2 4113/4885 |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | HTR3A 3135/4885PARP1 2803/4885SIRT2 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.